Last Updated on November 6, 2024 by The Health Master
Drug recall
Drug recall: Gilead Sciences, a leading pharmaceutical company, has made a significant announcement that will impact the lives of patients battling bladder cancer.
The company has voluntarily Drug recall, Trodelvy, from the market for patients who have previously undergone treatment for this condition.
This decision comes after careful consultation with the U.S. Food and Drug Administration (USFDA).
The USFDA’s Decision
Trodelvy, an antibody-drug conjugate, was initially granted accelerated approval by the USFDA in 2021 for the treatment of metastatic urothelial cancer.
This approval was contingent upon the results of a confirmatory clinical trial.
However, the drug failed to meet the primary endpoint of improving survival for patients with advanced bladder cancer in this trial.
Impact on Patients
The Drug recall of Trodelvy is undoubtedly a setback for patients with bladder cancer who were relying on this drug as a potential treatment option.
It is important to note that this decision does not affect the approval of Trodelvy for other patient populations, both within and outside the United States.
Financial Implications
The news of Drug recall of Trodelvy has had a noticeable impact on Gilead Sciences‘ stock price.
Shares of the company fell by 1.3% in premarket trading following the announcement.
This indicates that investors are concerned about the financial implications of the drug’s removal from the market.
Looking Ahead
While the Drug recall of Trodelvy is a disappointment, it is essential to remain hopeful about future developments in the field of bladder cancer treatment.
Researchers and pharmaceutical companies are continuously working to develop innovative therapies that can improve outcomes for patients.
It is likely that new treatment options will emerge in the coming years to address the unmet needs of this patient population.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Disclaimer: This content, provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. The Health Master does not claim responsibility for this information.
Drug recall: Glenmark recalls drugs for manufacturing issues
Drug recall: Baxter recalls various batches of Tisseel due to dissolution time
Drug recall: Dr Reddy’s, Lupin recall drugs over quality issue
Drug recall: B. Braun recalls Saline Solution due to this reason
Drug recall: Baxter recalls Heparin Sodium Injection Due to this reason
FSSAI: Food Labelling and Display – Chapter-11
USFDA approval granted for Fludrocortisone Acetate Tablets
Gujarat FDCA empowers Officers to enforce Revised Schedule M
Govt asks NPPA to recalculate ceiling price of Thiamine Injection
DTAB recommends changes to New Drugs and Clinical Trials Rules
NPPA revised Ceiling price of 11 scheduled formulations: October 2024
New Drugs, Medical Devices and Global Standards: India’s Regulatory Advancements
NPPA fixed retail price of 20 formulations: October 2024
19th ICDRA – Day 2nd: Key Highlights from the Workshop
Drug recall: Glenmark recalls drugs for manufacturing issues
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
